(CEO Wang Hoon-sik) announced on the 11th that it has obtained an item approval from the Ministry of Food and Drug Safety for a new salt-improving drug of Janumet XR (Sitagliptin Phosphate+ Metformin Hydrochloride.

GLPharmtech items licensed this time adopted Sitagliptin, a modified salt drug for Chong Kun Dang Sitaformin XR/Hanmi Pharmaceutical Sitamefor XR, which was designated as generic for exclusivity in 2016. GLPharmtech will be able to compete simultaneously, away from the influence of generic for exclusivity secured by Chong Kun Dang/Hanmi Pharmaceutical until June 1, 2024.

It plans to produce this product through technology transfer to Shinil, and will also be sold in Ildong, Don